Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
Nutriband Inc. (NASDAQ:NTRB) has extended its Chinese patent to Macao for its AVERSA™ abuse-deterrent transdermal technology, bringing the total patent coverage to 46 countries and territories. The Macao IP Office assigned patent number J/9010, effective December 17, 2024.
The AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, targeting FDA approval in the first half of 2025. The product has potential peak annual US sales of $80-200 million and aims to be the world's first abuse-deterrent opioid patch.
Nutriband Inc. (NASDAQ:NTRB) ha esteso il suo brevetto cinese a Macao per la sua tecnologia transdermica AVERSA™ a deterrente degli abusi, portando la copertura totale del brevetto a 46 paesi e territori. L'Ufficio della Proprietà Intellettuale di Macao ha assegnato il numero di brevetto J/9010, con effetto dal 17 dicembre 2024.
La tecnologia AVERSA™ integra agenti avversivi nei cerotti transdermici per prevenire abusi, diversioni, usi impropri e esposizione accidentale di farmaci con potenziale di abuso. Nutriband sta collaborando con Kindeva Drug Delivery per sviluppare AVERSA™ Fentanil, mirando all'approvazione della FDA nella prima metà del 2025. Il prodotto ha un potenziale di vendite annuali di picco negli Stati Uniti di 80-200 milioni di dollari e punta a essere il primo cerotto oppioide a deterrente degli abusi al mondo.
Nutriband Inc. (NASDAQ:NTRB) ha ampliado su patente china a Macao para su tecnología transdérmica AVERSA™ resistente al abuso, llevando la cobertura total de la patente a 46 países y territorios. La Oficina de Propiedad Intelectual de Macao asignó el número de patente J/9010, efectivo a partir del 17 de diciembre de 2024.
La tecnología AVERSA™ incorpora agentes aversivos en parches transdérmicos para prevenir el abuso, la desviación, el mal uso y la exposición accidental de medicamentos con potencial de abuso. Nutriband está colaborando con Kindeva Drug Delivery para desarrollar AVERSA™ Fentanilo, con el objetivo de obtener la aprobación de la FDA en la primera mitad de 2025. El producto tiene un potencial de ventas anuales en EE. UU. de 80 a 200 millones de dólares y busca ser el primer parche opioide resistente al abuso en el mundo.
Nutriband Inc. (NASDAQ:NTRB)는 AVERSA™ 남용 방지 경피 패치 기술에 대한 중국 특허를 마카오로 확장하여 총 특허 보호 범위를 46개 국가 및 지역으로 늘렸습니다. 마카오 지식재산권청은 2024년 12월 17일부터 유효한 특허 번호 J/9010을 부여했습니다.
AVERSA™ 기술은 남용, 전용, 오용 및 약물의 우발적 노출을 방지하기 위해 경피 패치에 혐오 물질을 통합합니다. Nutriband는 Kindeva Drug Delivery와 협력하여 AVERSA™ 펜타닐을 개발하고 있으며, 2025년 상반기 내 FDA 승인을 목표로 하고 있습니다. 이 제품은 미국에서 연간 8억에서 2억 달러의 판매 잠재력을 가지고 있으며, 세계 최초의 남용 방지 오피오이드 패치가 되는 것을 목표로 하고 있습니다.
Nutriband Inc. (NASDAQ:NTRB) a étendu son brevet chinois à Macao pour sa technologie transdermique AVERSA™ conçue pour prévenir les abus, portant la couverture totale des brevets à 46 pays et territoires. L'Office de la Propriété Intellectuelle de Macao a attribué le numéro de brevet J/9010, effet au 17 décembre 2024.
La technologie AVERSA™ intègre des agents aversifs dans des patchs transdermiques pour éviter les abus, la déviation, le mauvais usage et l'exposition accidentelle à des médicaments ayant un potentiel d'abus. Nutriband collabore avec Kindeva Drug Delivery pour développer AVERSA™ Fentanyl, visant l'approbation de la FDA au cours de la première moitié de 2025. Le produit a un potentiel de ventes annuelles aux États-Unis de 80 à 200 millions de dollars et vise à être le premier patch opioïde résistant aux abus au monde.
Nutriband Inc. (NASDAQ:NTRB) hat sein chinesisches Patent auf Macau für die AVERSA™ missbrauchsverhindernde transdermale Technologie ausgeweitet und damit den Patentumfang auf insgesamt 46 Länder und Gebiete erhöht. Das IP-Büro von Macau vergab die Patentsnummer J/9010, die ab dem 17. Dezember 2024 gültig ist.
Die AVERSA™-Technologie integriert aversive Stoffe in transdermale Pflaster, um Missbrauch, Abweichung, Fehlgebrauch und versehentliche Exposition gegenüber potenziell missbrauchbaren Medikamenten zu verhindern. Nutriband arbeitet mit Kindeva Drug Delivery zusammen, um AVERSA™ Fentanyl zu entwickeln, mit dem Ziel, in der ersten Hälfte von 2025 die FDA-Zulassung zu erhalten. Das Produkt hat ein potenzielles Jahresverkaufsvolumen in den USA von 80 bis 200 Millionen US-Dollar und zielt darauf ab, das weltweit erste missbrauchsverhindernde Opioid-Pflaster zu sein.
- Patent portfolio expanded to 46 countries, strengthening global intellectual property protection
- Partnership with established manufacturer Kindeva Drug Delivery for product development
- Potential peak annual US sales of $80-200 million for AVERSA Fentanyl
- Clear FDA approval timeline targeted for first half of 2025
- Product still in development phase with no current revenue generation
- FDA approval not guaranteed, presenting regulatory risk
Insights
Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets.
Nutriband is targeting to file for FDA approval for AVERSA™ Fentanyl in the first half of 2025.
ORLANDO, Fla., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has completed the registration requirements to extend its Chinese patent to Macao for its patent entitled, “Abuse and Misuse Deterrent Transdermal Systems,” which protects its AVERSA™ abuse deterrent transdermal technology.
The Macao IP Office has assigned number J/9010 to the patent with an entry date of December 17, 2024. Macao is a Special Administrative Region (SAR) of the People’s Republic of China which affords it a high degree of autonomy with its own patent system and patent laws which are separate and distinct from those of mainland China.
The Aversa™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia as well as two regions of China: Hong Kong and Macao.
Nutriband’s AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband is currently working with its partner Kindeva Drug Delivery (formerly 3M drug delivery systems), a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA™ Fentanyl, which incorporates Nutriband’s AVERSA™ abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of
__________________________________
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q’s filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Investor Relations
RedChip Companies, Inc.
Dave Gentry
Email: NTRB@Redchip.com
Phone: 1-800-RED-CHIP (733-2447)
or 407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
FAQ
When is Nutriband (NTRB) planning to file for FDA approval of AVERSA Fentanyl?
What is the projected peak annual US sales for NTRB's AVERSA Fentanyl?
How many countries now have patent protection for Nutriband's AVERSA technology?
What is the Macao patent number and entry date for NTRB's AVERSA technology?
Who is Nutriband's development partner for AVERSA Fentanyl?
